ABSTRACT
Objective: To assess the prevalence of psychiatric comorbidities in patients with neurofibromatosis.
Methods: In this cross-sectional study, we used the 2010–2014 National Inpatient Sample database. Patients ≥ 18 years of age with a primary or secondary diagnosis of neurofibromatosis and psychiatric comorbidities were queried.
Results: A total of 43,270 patients with a mean age of 48.7 years (female: 55.7%, White: 70.1%) were included in the study. Overall, psychiatric comorbidities were present in 46.5% of patients; mood disorders (22.1%) and anxiety disorders (12.2%) were the most prevalent comorbidities. Although previous studies report prevalence rates of attention-deficit/hyperactivity disorder in up to 50% of patients with neurofibromatosis, our study found that the rate was much lower at 1.10%. Female sex and non-White race were less associated with psychiatric comorbidities (odds ratio = 0.868 [P = .003] and 0.689 [P < .001], respectively). The moderate-to-extreme loss of function illness severity category was associated with 1.35-times higher odds of having psychiatric comorbidities compared to mild-to-moderate or no loss of function (P < .001). The total length of stay was similar in patients with and without psychiatric comorbidities (mean = 4.98 [95% CI, 4.72–5.24] vs mean = 4.83 [95% CI, 4.60–5.07], respectively; P = .34).
Conclusions: In adult patients with neurofibromatosis, 46.5% were found to have at least one psychiatric comorbid diagnosis. The most frequent psychiatric comorbid disorders were mood disorders and anxiety disorders. Female sex and non-White race predicted a lower likelihood of having a psychiatric disorder.
Prim Care Companion CNS Disord 2023;25(5):23m03514
Author affiliations are listed at the end of this article.
Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
References (16)
- Belzeaux R, Lançon C. Neurofibromatose de type 1: troubles psychiatriques et altération de la qualité de vie. (Neurofibromatosis type 1: psychiatric disorders and quality of life impairment) Presse Med. 2006;35(2 Pt 2):277–280. PubMed CrossRef
- HCUP-US NIS overview. HCUP-US. AHRQ website. Accessed August 2020. https://www.hcup-us.ahrq.gov/nisoverview.jsp
- Clinical Classifications Software Refined (CCSR). Healthcare Cost and Utilization Project (HCUP). March 2021. Agency for Healthcare Research and Quality, Rockville, MD. Accessed August 1, 2020. www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp
- Evans DG. Neurofibromatosis type 2. Handb Clin Neurol. 2015;132:87–96. PubMed CrossRef
- Mansukhani SA, Butala RP, Shetty SH, et al. Familial schwannomatosis: a diagnostic challenge. J Clin Diagn Res. 2017;11(2):RD01–RD03. PubMed
- Le C, Bedocs PM. Neurofibromatosis. In: StatPearls. Treasure Island, FL: StatPearls Publishing; January 2022. Accessed November 2022. https://www.ncbi.nlm.nih.gov/books/NBK459329/
- Ghalayani P, Saberi Z, Sardari F. Neurofibromatosis type I (von Recklinghausen’s disease): a family case report and literature review. Dent Res J (Isfahan). 2012;9(4):483–488. PubMed
- Antinheimo J, Sankila R, Carpén O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54(1):71–76. PubMed CrossRef
- Gutmann DH, Ferner RE, Listernick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004. PubMed CrossRef
- Mautner VF, Kluwe L, Thakker SD, et al. Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol. 2002;44(3):164–170. PubMed CrossRef
- Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993;363(6429):515–521. PubMed CrossRef
- Hulsebos TJ, Kenter SB, Jakobs ME, et al. SMARCB1/INI1 maternal germ line mosaicism in schwannomatosis. Clin Genet. 2010;77(1):86–91. PubMed CrossRef
- DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105(3 Pt 1):608–614. PubMed CrossRef
- Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52(4):450–461. PubMed CrossRef
- Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84(304):603–618. PubMed
- Cohen JS, Levy HP, Sloan J, et al. Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life. Clin Genet. 2015;88(5):425–430. PubMed CrossRef
Please sign in or purchase this PDF for $40.
Save
Share
Cite
